Back to User profile » Dr Grossi
Paper published by Dr Grossi:
Original Research
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:31-37
Published Date: 26 January 2012